General
Preferred name
BENDAZAC
Synonyms
BENDAZAC LYSINE ()
Bendazaco lisina ()
Bendazac L-lysine ()
bendazac lysinate ()
bendazolic acid, AF-983 ()
2-(1-Benzyl-1H-indazol-3-yloxy)acetic Acid ()
Bindazac ()
Iwazac ()
AF 1934 [LYSINE] ()
P&D ID
PD013783
CAS
81919-14-4
20187-55-7
Tags
available
drug
Drug Status
approved
withdrawn
Max Phase
Phase 4
Drug indication
Anti-Inflammatory
First approval
1984
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Prior to the withdrawal of bendazac from various international regions of use due to concerns for hepatotoxicity [A39891, A39892, A39893, L4778] the chemical had demonstrated potential usefulness predominantly as the prescription medication bendazac lysine for the indication of managing the level of vision in patients with mild to moderate cataracts to facilitate delaying the need for surgical intervention [A39863, A39869, A39890].; ; Elsewhere bendazac may still be available in a limited capacity as a non-prescription topical cream product for treating conditions like local pain, inflammation, dermatitis, eczema, pruritis, hives, insect bites, burns, erythema, and others [L4780] - although such products may also be facing general discontinuation [L4781].
PHARMACODYNAMICS
Bendazac principally demonstrates an antidenaturant action on proteins [A39863, A39869]. This effect has been shown to inhibit the denaturation of various proteins like ocular lens proteins by heat, ultraviolet radiation, free radicals, and other chemicals [A39863, A39869]. The medication may be administered to patients via a number of different formulations, including orally as the lysine salt, as eye drops, or even topical applications for the skin [A39863, A39869].; ; Some preliminary studies have suggested that an apparent improvement of the blood-retinal barrier had been observed in diabetic patients using bendazac lysine 500 mg three times a day for three to six months [A39869]. Moreover, the use of topical bendazac has also been shown to demonstrate anti-inflammatory effects in animal models and clinical studies to effectively treat varied dermatoses, especially those involving a necrotic component [A39869].; ; Additionally, bendazac has also demonstrated choleretic and antilipidaemic activities that have resulted in substantial reductions in beta/alpha lipoprotein ratio, and total lipid, total cholesterol, and triglyceride levels in patients with dyslipidaemia using oral bendazac lysine 500 mg three times daily [A39863, A39869]. The medication has also elicited the inhibition of phytohaemagglutinin induced lymphocyte transformation in vitro [A39863, A39869].
MOA
Bendazac seems to elicit an anticataract action by inhibiting the denaturation of ocular lens proteins, although the precise mechanisms by which this action occurs has not yet been formally elucidated - despite there being many proposed mechanisms [A39863, A39869]. In particular, the denaturation of lens proteins may in part be prevented by inhibiting the binding of certain chemicals like cyanates or sugars and 5-hydroxybendazac - the major metabolite of bendazac - has been shown to be capable of inhibiting the glycosylation of lens proteins by sugars like galactose or glucose-6-phosphate in a dose-dependent manner [A39869]. Moreover, the apparent ability for administered bendazac to elicit free radical scavenger activities due to interactions with protein molecules suggests that the medication may also be able to prevent the oxidation of lens proteins by free radicals in the development of cataracts [A39863, A39869]. Furthermore, bendazac may also be capable of reducing the sulfhydryl group oxidation of lens proteins by the saliva, serum, or urine from patients with cataracts following single dose administration and reduce biological liquid oxidant activity (BLOA) in doing so [A39869].; ; Otherwise, it is believed that bendazac also possesses non-steroidal anti-inflammatory actions, as well as analgesic, antipyretic, and platelet-inhibitory effects [L4782, T332] These effects may be accounted for in part by the substance's capability to inhibit prostaglandin synthesis by inhibiting cyclooxygenase activity in converting arachidonic acid to cyclic endoperoxides - the precursors of prostaglandins [L4782, T332].
DESCRIPTION
Bendazac is a non-steroidal anti-inflammatory drug (NSAID) used for joint and muscular pain, which is also known as AF-983 (an anticataract drug). It was found to inhibit only reversible and irreversible xanthine oxidase. Bendazac also inhibits the denaturing of proteins.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
282.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.55
TPSA
64.35
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Disease Area
neurology/psychiatry, rheumatology
Indication
muscle pain, joint pain
Target
PTGS1, PTGS2
Immunology & Inflammation related
MOA
cyclooxygenase inhibitor
ATC
M02AA11
S01BC07
Toxicity type
hepatic
Solubility
DMSO (Slightly), Methanol (Slightly, Heated)
Source data
